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A. Santos b,g,* 
a Department of Health Sciences, University of Catanzaro “Magna Græcia”, Campus Universitario “S. Venuta”, Viale Europa, I-88100 Catanzaro, Italy 
b Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland 
c Department of Pharmacy, University of Chieti-Pescara “G. d’Annunzio”, Via dei Vestini 31, I-66100 Chieti, Italy 
d Department of Experimental and Clinical Medicine, University of Catanzaro “Magna Græcia”, Campus Universitario “S. Venuta”, Viale Europa, I-88100 Catanzaro, 
Italy 
e Department of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland 
f Laboratory for Cancer Biology, University of Tartu, Tartu 50411, Estonia 
g Helsinki Institute of Life Science (HiLIFE), University of Helsinki, FI-00014 Helsinki, Finland   





Targeted therapy: multidrug approach 
A B S T R A C T   
Breast cancer, with around 2 million new cases in 2019, is the second most common cancer worldwide and the 
second leading cause of cancer death among females. The aim of this work is to prepare a targeting nanoparticle 
through the conjugation of LinTT1 peptide, a specific molecule targeting p32 protein overexpressed by breast 
cancer and cancer associated cells, on liposomes’ surface. This approach increases the cytotoxic effects of 
doxorubicin (DOX) and sorafenib (SRF) co-loaded in therapeutic liposomes on both 2D and 3D breast cancer 
cellular models. The liposome functionalization leads to a higher interaction with 3D breast cancer spheroids 
than bare ones. Moreover, interaction studies between LinTT1-functionalized liposomes and M2 primary human 
macrophages show an internalization of 50% of the total nanovesicles that interact with these cells, while the 
other 50% results only associated to cell surface. This finding suggests the possibility to use the amount of 
associated liposomes to enrich the hypoxic tumor area, exploiting the ability of M2 macrophages to accumulate 
in the central core of tumor mass. These promising results highlight the potential use of DOX and SRF co-loaded 
LinTT1-functionalized liposomes as nanomedicines for the treatment of breast cancer, especially in triple 
negative cancer cells.   
1. Introduction 
Breast cancer is the second most commonly diagnosed cancer 
worldwide and the second leading cause of cancer death among women 
(Bray et al., 2018). The statistics indicate that about 16.2% of 850,000 
cancer deaths in 2018 in European countries were associated to breast 
cancer (Dafni et al., 2019), and 279,100 new breast cancer cases are 
estimated to occur in the United States in 2020 (Siegel et al., 2020). 
Oncological patients who have been diagnosed with breast cancer can be 
subjected to different therapies, such as surgery, radiation therapy and 
chemotherapy, often used in association (Akram et al., 2017). Despite 
the improved survival rate during the last three decades (DeSantis et al., 
2019), mainly due to the early diagnosis (Hawkes, 2019; Wang, 2017) 
and the development of endocrine and hormone receptor targeted 
treatments (Masoud and Pagès, 2017; Tremont et al., 2017), conven-
tional chemotherapies still play a crucial role in adjuvant and neo-
adjuvant setting (Waks and Winer, 2019), especially in triple negative 
breast (TNB) cancer that are not responsive to hormonal therapies 
(Wahba and El-Hadaad, 2015). Unfortunately, conventional chemo-
therapeutic agents show several restrictions: (i) inadequate 
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pharmacokinetic profiles; (ii) physicochemical instability after in vivo 
administration; (iii) the development of resistance mechanisms; and (iv) 
the poor or lack specificity towards the pathological tissues. These 
drawbacks lead to several side effects, which strongly compromise the 
patients’ health and decrease their compliance to the therapies, thus 
making priority the development of a “new generation” of chemother-
apeutic agents (Arruebo et al., 2011; Wicki et al., 2015; Du et al., 2019). 
In this scenario, the use of nanocarriers as drug delivery systems 
(DDSs) had a significant impact in cancer therapy, as shown by the 
presence of nanomedicines that are currently available on the market 
like Doxil®, Myocet®, Abraxane®, Onivyde® DaunoXome®, Thermo-
Dox® and many others in clinical trials for the treatment of breast cancer 
(Anselmo and Mitragotri, 2019; Di Wu et al., 2017). The use of DDSs 
overcomes several limitations related to the conventional chemother-
apies, by preserving payloads from degradation (Maggisano et al., 
2019), providing a sustained and controlled release (Yong et al., 2019; 
Barone et al., 2019), and increasing the therapeutic efficacy by allowing 
the selective targeting of nanocarriers to the tumor tissue (Almeida 
et al., 2014), thus improving the pharmacokinetic profiles (Unnam et al., 
2019; Celia et al., 2021) and decreasing the administration frequency of 
drug dosage (Bulbake et al., 2017). 
In particular, liposomes have been widely studied as drug delivery 
systems for anticancer use due to their biocompatibility (Wolfram et al., 
2014a,b), the high formulation versatility that provides a nanoplatform 
to the delivery of hydrophilic and lipophilic payloads (as single agents or 
combination) (Cosco et al., 2012) and the opportunity to modify their 
physicochemical characteristics, such as size, surface properties and 
composition (Olusanya et al., 2018). These last features can be oppor-
tunely optimized in order to take advantage from pathophysiological 
changes that occur into the tumor microenvironment (TME), increasing 
the nanoparticle specificity (Olusanya et al., 2018). 
Liposomes can be properly modified, by conjugating directly to 
phospholipids and/or polymers (Riaz et al., 2018) specific ligands 
capable to target selectively receptors overexpressed in TME compo-
nents, thus improving their accumulation inside the tumor tissue and 
increasing their therapeutic effects (Paolino et al., 2014; Luo et al., 
2020). To date, several molecules, i.e. antibodies, peptides and proteins, 
are used to modify the surface of DDSs and provide targeted breast 
cancer therapies (Khan et al., 2015). In particular, tumor homing pep-
tides are one of the most promising strategies in this field (Singh et al., 
2019; Qu et al., 2017). These molecules consist of <30 amino acids and 
are accumulated in the tumor tissues, providing a potential use as spe-
cific targeting and diagnostic agents in cancer therapy (Laakkonen and 
Vuorinen, 2010). These peptides have several advantages compared to 
other targeting molecules, such as higher tumor penetrating properties 
than conventional antibodies, cheap synthetic process, higher selectivity 
than small targeting molecules, i.e. aptamers, and non-immunogenic 
properties (Vlieghe et al., 2010). In these attempts, the trans-mem-
brane gC1q receptor (gC1qR), also known as p32 protein, is one of the 
most promising molecules to target aggressive adenocarcinoma, such as 
breast cancer (Saha and Datta, 2018; Peerschke and Ghebrehiwet, 2014; 
Rubinstein et al., 2004). The protein p32 is over-expressed on the 
cellular surface of cancer (Rubinstein et al., 2004; Fogal et al., 2008) and 
tumor associated cells, like active angiogenic endothelial cells, cancer 
associated fibroblast, and tumor associated macrophages (TAMs) 
(Agemy et al., 2013; Sharma et al., 2017). The protein p32 is further 
overexpressed in malignant cancers (Peerschke et al., 2019) and play a 
crucial role in tumor progression (Saha and Datta, 2018; Chen et al., 
2009). These results demonstrated that p32 protein is a new target for 
breast cancer, and particularly TNB cancers, where the common re-
ceptors that are currently used for targeted therapy are lacking (Khos-
ravi-Shahi et al., 2019). 
Linear TT1 (LinTT1) peptide (AKRGARSTA), a specific molecule 
targeting p32 protein (Simón-Gracia et al., 2018b; Simón-Gracia et al., 
2018a), was used in this study to modify the surface of liposomes. As a 
result of its lower affinity for p32 protein in comparison with parental 
disulfide-bridged cyclic TT1 peptide, it showed a limited interaction 
with the receptor located on “binding-site barrier” in the TME, resulting 
in an increased extravasation and a significant accumulation in inner 
tumor tissues (Sharma et al., 2017). Furthermore, as previously 
demonstrated in vivo, urokinase-type plasminogen activator (uPA), a 
serine protease aberrantly expressed in malignant tumor, makes the 
cleavage of LinTT1 peptide, leading to the exposition of C-end moiety 
(AKRGAR) (Simón-Gracia et al., 2018b; Braun et al., 2016). This C-end 
Rule (CendR) motif binds the transmembrane receptor Neuropilin-1 
(NRP-1) wich results over-expressed in tumor tissue, leading to an 
improved penetration of the peptide and conjugated-cargo into the 
tumor (Simón-Gracia et al., 2018b). 
The aim of this work was the design and synthesis of therapeutic 
targeting liposomes through the conjugation of LinTT1 peptide onto the 
surface of preformed liposomes. The resulting functionalized liposomes 
were physicochemically characterized and the conjugation of peptide to 
liposomal surface was measured by elemental and fluorescent analysis, 
while blood safety was evaluated using human red blood cells (RBCs). 
Sorafenib (SRF) and doxorubicin hydrochloride (DOX) were co-loaded 
inside the LinTT1-functionalized liposomes (LinTT1-Lipo) to provide a 
synergistic effect of the two drugs, and improve the cytotoxic activity of 
liposomal doxorubicin (Doxil®/Caelyx® or Myocet®) that is currently 
on market and used in clinic. Despite SRF is currently approved for 
hepatocellular (Keating, 2017), iodine resistant thyroid (Pitoia and 
Jerkovich, 2016) and renal cell carcinoma (Wilhelm et al., 2006), 
several studies demonstrated its efficacy in breast cancer therapies when 
it was co-administered with other drugs which are commonly used in 
breast anticancer therapy (Lei et al., 2019; Chen et al., 2019a). The 
anticancer activity of therapeutic LinTT1-Lipo was evaluated on both 2D 
(MCF-7 and MDA-MB-231 cells) and 3-D (MDA-MB-231) cancer cell 
models. The interaction between LinTT1-Lipo and 3D spheroids was 
evaluated in vitro by flow cytometry and confocal laser scanning mi-
croscopy analyses. Finally, the interaction between LinTT1-Lipo and 
primary human M2 macrophages was also studied. TAMs are commonly 
present in TME and play a crucial role in cancer progression (Chen et al., 
2019b). In response to the physical stimuli in TME, such as hypoxia in 
the tumor core area and the high levels of chemokine, i.e. IL-4, TAMs 
population is off-balanced toward M2-phenothype, thus showing onco-
genic properties (Chen et al., 2019b; Park et al., 2019). For these rea-
sons, the targeting of TAMs is one of the most promising approaches to 
prepare innovative anticancer nanomedicines (Cassetta and Pollard, 
2018). In this investigation, we focused our efforts on the opportunity to 
use these cells to increase the liposomes accumulation in tumor core 
through a “cellular hitchhiking” approach (Torrieri et al., 2020). We 
hypothesize that this approach and the intrinsic ability of these cells to 
accumulate in the central area of the solid tumor, could increase the 
drug concentration in the hypoxic tumor tissue where anticancer ther-
apy with drug delivery systems that are currently used have failed so far. 
2. Materials and methods 
2.1. Materials 
Cholesterol (CHOL), trypan blue solution and polysorbate 80 (Tw80) 
were obtained from Sigma-Aldrich. 1,2- dipalmitoyl-sn-glycero-3-phos-
pocholine (DPPC), N-(carbonyl-methoxypolyethylene glycol-2000)-1,2- 
distearoylsn-glycero-3 phosphoethanolamine (DSPE-mPEG2k), 1,2-dis-
tearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene 
glycol)-2000] (DSPE-PEG2000mal) and Ganglioside were purchased 
from Avanti Polar (Suffolk, UK). Doxorubicin hydrochloride (DOX) was 
provided from Tokyo Chemical Industry Co. Ltd, Japan. Hank’s balance 
salt solution (HBSS), trypsin, Dulbecco’s modified Eagle’s medium 
(DMEM), Rosewell Park Memorial Institute (RPMI) culture-medium, 
penicillin–streptomycin (PEST), L-glutamine, fetal bovine serum (FBS), 
non-essential amino acids (NEAA) and phosphate buffered saline (PBS) 
solution were provided from HyClone (USA). N-(fluorescein-5- 
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tiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine 
triethylammonium salt (fluorescein-DHPE) and DAPI-405 were pur-
chased from Thermo Fisher Scientific Co. (St. Louis, USA). Sorafenib 
(SRF) was obtained from LC laboratories® (USA). Paraformaldehyde 
(PFA) was purchased from Sigma-Aldrich,USA. Ficoll-Paque was ob-
tained from GE Healthcare Bio-sciences (Piscataway, NJ). All the other 
reagents used in the experiments were of analytical grade. 
Human breast cancer cell lines (MDA-MB-231 and MCF-7) and 
human Foreskin fibroblast cell lines were obtained from American Type 
Culture Collection (ATCC), USA. Red blood cells and M2 macrophages 
were collected starting from Heparin-stabilized fresh human blood 
provided by the Finnish Red Cross Blood Service by anonymous donors. 
2.2. Synthesis of LinTT1-liposomes 
Liposomes were synthesized using the thin layer evaporation (TLE) 
method (Paolino et al., 2014). Briefly, lipids were dissolved in round- 
bottomed vials using an organic solvent mixture (chloroform/meth-
anol 3:1 v/v). The final lipid molar ratio was 6:3:0.6:0.4 for DPPC:CHOL: 
GANGLIOSIDE:DSPEmPEG2000-maleimmide, respectively. The organic 
solvents were removed using a rotavapor Büchi R-210 at 40 ◦C (Flawil, 
Switzerland) and the residual solvent was dried overnight by a Büchi 
T51 glass drying oven (Flawil, Switzerland) connected to a vacuum 
pump. The resulting lipid film was hydrated with a PBS solution (10 mM, 
pH 7.4) to obtain a final lipid concentration of 20 mg mL− 1. Three 
alternate cycles (3 min each) of warming at 60 ◦C, in a thermostatic 
water bath, and vigorous mixing, by vortex at 750 rpm, were used 
during the hydration process. The resulting multilamellar liposomes 
were kept at 60 ◦C for 1 h to anneal the bilayer structure and then 
extruded by a Lipex extruder at 60 ◦C (Vancouver, Canada) through 
polycarbonate membrane filters with pore sizes from 800 to 100 nm 
(Nucleopore® Polycarbonate). After extrusion, the liposomal suspension 
was incubated with a PBS solution (10 mM, pH 7.4) containing LinTT1 
peptide (lipid:peptide ratio at 60:1 w/w) for 3 h at room temperature 
under continuous magnetic stirring (≈200 rpm). The obtained LinTT1- 
functionalized liposomes (LinTT1-Lipo) was purified by Amicon® 
Ultra centrifugal filters (cut-off 100 kDa, 13000 rpm for 5 min) and 
washed twice with fresh PBS solution (10 mM, pH 7.4). 
To obtain therapeutic LinTT1-functionalized liposomes, SRF, if 
necessary, was added to lipid mixture with a final concentration of 0.5 
mg mL− 1 of drug per final volume of liposomes, while DOX was 
entrapped using a pH gradient and remote loading procedure (Bare-
nholz, 2012). Briefly, for DOX loading, lipid film hydration was obtained 
using an ammonium sulphate solution (250 mM, pH 5.5), followed by 
warming and extrusion, as described above. After extrusion, liposomes 
were centrifuged at 90,000g for 1 h, at 4 ◦C by using a Beckman Opti-
maTM Ultracentrifuge (Fullerton, Canada). The resulting pellet was re- 
suspended with a DOX solution to have a final drug concentration of 
1 mg mL− 1 (PBS 10 mM, pH 7.4). The samples were then heated for 1 h 
up to the transition temperature or Tm (60 ◦C), and under continuous 
stirring to facilitate the DOX crystallization in the aqueous core of li-
posomes. The unentrapped DOX was removed by a dialysis tube (cut-off 
10,000 Da, Spectrum Labs, Breda, Netherlands) under continuous slowly 
stirring at room temperature for 2 h. A fresh PBS solution (10 mM; pH 
7.4) was used as receptor medium. Then the peptide was conjugated to 
therapeutic liposomes, as described above. 
Unconjugated liposomes (bare-Lipo) were synthetized using the 
same procedures as described above by replacing DSPEmPEG 2000-mal-
eimide with DSPEmPEG2000 at the same molar ratio. When required, 
fluorescent liposomes were obtained by adding DHPE-fluorescein (0.1% 
w/w) to the lipid mixture of bare-Lipo during the preparation proced-
ure, while LinTT1-functionalized liposomes were per se fluorescent due 
to FAM group included in the backbone structure of the peptide. 
2.3. Physicochemical characterization 
The average hydrodynamic diameter, polydispersity index (PDI) and 
zeta-potential were measured with a Zetasizer Nano ZS (Malvern In-
struments Ltd, Malvern, UK), set with a 4.5 mW laser diode, operating at 
670 nm, and a detection angle of 173◦. Samples were properly diluted 
50-folds with PBS or MilliQ-water for size and zeta-potential analyses, to 
avoid multi-scattering phenomena. Results were expressed as the 
average of three different experiments ± S.D. Moreover, the concen-
tration of nanovesicles (liposomes/mL) was quantified by using Zeta-
sizer Ultra (Malvern Panalytical Instruments Ltd, Malvern, UK) and this 
parameter was used to calculate the density of LinTT1 conjugated to 
liposomal surface. 
FTIR analysis was obtained on freeze-dried liposomes using a FTIR 
instrument (Vertex 70, Bruker, USA). The resulting ATR-FTIR spectra 
were recorded between 3600 and 700 cm− 1 with a resolution of 4 cm− 1 
using an OPUS 5.5 software, at room temperature. 
The elemental composition of bare-Lipo and LinTT1-Lipo, for the 
relative percentages of carbon (C), hydrogen (H), nitrogen (N) and sulfur 
(S), was measured on freeze-dried samples by using a Vario MICRO cube 
CHNS analyzer (Elementar Analysensysteme GmbH, Langenselbold, 
Germany). Different nitrogen percentage amounts between the two 
samples were used to confirm the conjugation of LinTT1 on the surface 
of liposomes via PEG. The instrument was daily calibrated through 
sulphanilamide, that is the recommended calibration standard to 
calculate the systematic error for each analysis (Vergallo et al., 2020). 
The successful conjugation of LinTT1 peptide was also confirmed by 
a Varioskan™ LUX multimode microplate reader (Thermo Fisher Sci-
entific Inc., USA). Briefly, after purification the fluorescence of LinTT1 
peptide was measured after its conjugation to liposomal surface and the 
analysis was carried out by measuring the fluorescence of 5-FAM group 
that is included in the backbone structure of peptide. Data was 
compared with fluorescent signals of bare-Lipo. A wavelength of 495 
and 515 nm were used as excitation and emission wavelength, respec-
tively, during the analysis. 
Finally, the peptide’s conjugation efficiency on liposomes surface, 
was also evaluated in a fluorescent mode, using a suitable calibration 
curve (Figure S1). 
TEM analysis was carried out, as described elsewhere (Barone et al., 
2020). Briefly, liposomes were appropriately diluted (1:200, v/v) in 
isotonic and inert buffer, and then deposited on 200-mesh formvar- 
coated copper grid (TABB Laboratories Equipment, UK). The resulting 
samples were stained by uranyl acetate solution (2%, w/v) and then 
dried at 23 ◦C. The images were acquired using a JEM 2010 microscope 
(Jeol, MA, USA) (Figure S2 and S3). 
2.4. NMR analysis 
The conjugation of LinTT1 to DSPE-PEG2000mal by sulfhydryl- 
maleimide reaction was tested by 1H NMR, as reported elsewhere with 
some modifications (Wang et al, 2019). Briefly, LinTT1 was dissolved in 
PBS (pH = 7.4, 10 mM), while DSPE-PEG2000mal was dissolved in N,N 
dimethylformamide (DMF). The resulting lipid solution was then added 
to the LinTT1 solution under continuous magnetic stirring at room 
temperature. The final molar ratio between peptide and DSPE- 
PEG2000mal was 1.5:1. After 3 h of incubation, the excess of DMF 
and unconjugated peptide was removed by dialysis using a dialysis tube 
of 3.5 kDa (Spectra/Por 1 Standard RC Dry Dialysis Tubing, Spectrum 
Labs, USA.) versus deionized water. The dialysis was carried out at room 
temperature for 6 h. The resulting product was freeze-dried (Christ 
Alpha 1–4 LCG, Osterode am Harz Germany), and then analyzed by 
Varian Mercury 300 MHz instrument (Varian Inc., Palo Alto, CA, USA). 
The analysis was carried out according to manufacture instructions and 
software set-up of both instruments, and 1H NMR of LinTT1, DSPE- 
PEGmal, and DSPE-PEGmal-LinTT1 was analyzed (Figure S4). 
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2.5. Hemocompatibility test 
Red blood cells (RBCs) were isolated starting from whole human 
blood and used to evaluate the hemocompatibility of LinTT1- 
functionalized liposomes, as reported elsewhere (Shahbazi et al., 
2013; Yu et al., 2011; Bhatt et al., 2018). Briefly, RBCs were washed for 
five times with sterile PBS (10 mM, pH 7.4). About 2 mL of cell sus-
pension was then diluted up to 40 mL with PBS (≈5% hematocrit). This 
diluted RBC suspension (0.1 mL) was added to LinTT1-Lipo (0.4 mL) 
that has been previously diluted with PBS in order to have a final lipid 
concentration of 25, 50, 100, and 200 µg mL− 1. The resulting suspension 
was gently mixed and then incubated under continuous shaking at 37 ◦C, 
for 48 h. At fixed time points (1, 4, 8, 12, 24, and 48 h), samples were 
vortexed again and centrifuged for 5 min at 13,000 rpm. For each time 
point, 100 µL of the supernatant were transferred to a 96-well plate and 
the absorbance of hemoglobin was measured at 577 nm, using a refer-
ence wavelength of 655 nm. The analysis was carried out by a Vari-
oskan™ LUX multimode microplate reader (Thermo Fisher Scientific 
Inc., USA). MilliQ-water and PBS solution (0.4 mL) were used as positive 
and negative controls, respectively, during the analysis. 
2.6. Drugs loading capability and in vitro release kinetic of liposomes 
Liposomes were lyophilized and then disrupted with cooled absolute 
methanol and the amount of DOX and/or SRF entrapped inside lipo-
somes were evaluated by VarioskanTM LUX multimode microplate 
reader (Thermo Fisher Scientific Inc., USA) and HPLC, respectively. 
Empty liposomes with the same lipid composition were used as blank 
during the analysis. For both drugs, the entrapment efficiency (E.E.%) 









× 100 (2) 
where, Den is the amount of encapsulated drug, Dtot is the total 
amount of drug added during preparation procedure and Lw is the 
amount of lipids used to make liposomes. The HPLC analysis for SRF 
quantification was performed, as reported elsewhere (Almeida et al., 
2017). The analysis was carried out using a C18 column (4.6 × 100 mm, 
3 μm, Gemini-Nx plus C18; Phenomenex, CA, USA) at room tempera-
ture. The mobile phase consisted of 0.2% (v/v) of trifluoroacetic (TFA) 
acid buffer (pH 2) and acetonitrile (42:58 v/v ratio), and the flow rate 
was set at 1.0 mL min− 1. For each sample, 20 μlL was injected and SRF 
was detected at the maximum wavelength of 254 nm. For DOX quanti-
fication, 100 µL of disrupted liposomes were placed in a 96-well plate 
and drug was detected by a VarioskanTM LUX multimode microplate 
reader (Thermo Fisher Scientific Inc., USA) in a fluorescent mode (λex 
470 nm; λem 585 nm). An appropriate external calibration curve for each 
drug was used to calculate the amount of DOX and SRF entrapped inside 
the liposomes (Figure S5). SRF amount to be included in the lipid bilayer 
of liposomes was studied and the one that provided the maximum drug 
loading efficiency percentage (Figure S6), was selected for further 
studies. 
In vitro drug release of DOX and SRF co-loaded into LinTT1- 
functionalized liposomes (LinTT1-Lipo/D + S) was evaluated by the 
dialysis bag method, using a cellulose acetate dialysis tube (Spectra/Por 
1 Standard RC Dry Dialysis Tubing, 12–14 kDa, Spectrum Labs, USA.). 
Two different solutions were used as receptor medium for DOX and SRF: 
PBS solution supplemented with 1% (v/v) of Tw80 and PBS solution 
supplemented with 10% of FBS. The receptor medium was adjusted to 
have a final pH of 7.4, 6.5 and 5.5. Liposomes (1 mL) were placed in the 
dialysis bag and transferred into a beaker containing 100 mL of the re-
ceptor medium. The release medium was constantly warmed (37 ±
0.5 ◦C) and gently stirred up to 72 h of incubation (GR 150 thermostat, 
Grant Instruments Ltd., Cambridge, UK). At fixed time points, 1 mL of 
receptor medium was withdrawn and replaced with the same volume of 
fresh fluid. Samples were then analyzed by HPLC and by VarioskanTM 
LUX multimode microplate reader (Thermo Fisher Scientific Inc., USA) 
for SRF and DOX, respectively. To remove the autofluorescence of serum 
proteins, and thus, prevent potential interferences during the analysis, 
the collected samples were pre-treated, as reported elsewhere (Charrois 
and Allen, 2004; Di Francesco et al., 2021). Briefly, samples were mixed 
with slight acid methanol (sample/methanol 1:3, v/v, ratio) and then 
stirred for 1 min. The resulting mixture was then centrifuged (11,500g 
for 10 min) and the supernatant was used for the analysis. A sample 
containing only the receptor medium was used as blank for different 
media and pH values to normalize the resulting data. Equation (3) was 







× 100 (3) 
where, drugrel is the amount of drug released at selected time point, 
drugload is the amount of drug entrapped inside liposomes and d.f. is the 
dilution factor that was used during the analysis. To optimize results, the 
drug release was calculated using the appropriate external calibration 
curves consisting of the same buffer used during release studies 
(composition and pH values) of DOX and SRF (Figure S7 and S8). Results 
are the average of three independent experiments ± S.D. 
2.7. Stability studies in human plasma. 
The human plasma stability of DOX/SRF-co-loaded LinTT1-func-
tionalized liposomes was tested with some modifications, as previously 
reported elsewhere (Almeida et al., 2014). The human plasma was pu-
rified starting from the whole human blood obtained from anonymous 
donors through the Finnish Red Cross Blood Service. The human plasma 
was isolated and collected as reported in the Section 2.11 and stored at −
20 ◦C until the day of experiment. Briefly, 400 μL of DOX/SRF-co-loaded 
LinTT1-functionalized liposomes were incubated with 2 mL of medium 
(saline solution NaCl 0.9%/human plasma, 50:50 (v/v)) at 37 ◦C. The 
resulting mixture was maintained under continuous stirring (300 rpm) 
up to 72 h. At fixed time points (30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, 48 h, 
72 h) 100 µL of samples was withdrawn and its relative average size 
(liposomes) was measured by DLS. The resulting data was compared to 
that obtained for HSPC:Chol:DSPE-PEG2000 (6.5:3:0.5 lipid molar 
ratio) loading DOX (2 mg/mL) (Caelyx-like Lipo) which is similar to 
Doxil/Caelyx commercial liposomes. The incubation of liposomes with 
saline solution (0.9% NaCl) was used as negative control (data not 
shown). 
The stability of DOX/SRF-co-loaded LinTT1-functionalized lipo-
somes and Caelyx-like Lipo (control) was analyzed using Turbiscan 
Lab® Expert (L’Union, France), which can predict the potential desta-
bilization phenomena (sedimentation, coagulation or flocculation) of 
intact liposomes and colloidal nanocarriers in general, as reported 
elsewhere (Caddeo et al., 2018; Tai et al., 2018). Turbiscan Lab® Expert 
analysis was used to test how the human plasma can affect the stability 
of DOX/SRF-co-loaded LinTT1-functionalized liposomes and Caelyx-like 
Lipo (control). Briefly, 600 µL of liposomes were diluted up to 6 mL with 
medium (saline solution NaCl 0.9%/human plasma, 50:50 (v/v)) or with 
saline solution (NaCl 0.9%), as a negative control. The resulting mix-
tures were then placed into a glass tube and analyzed for 1 h. The 
analysis was carried out at 37 ◦C, which is equivalent to body temper-
ature, using a pulsed near infrared LED (wavelength set at 880 nm). 
Significant variation of Back Scattering (ΔBS) and Transmission (ΔT) 
signals vs sample height (Figura S9 and S10) were used to test the po-
tential destabilization phenomena of liposomes (Celia et al., 2009). 
Moreover, the destabilization kinetic profile vs incubation time was 
further evaluated (Figure S11). 
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2.8. 3D tumor spheroids preparation 
3D spheroids of MDA-MB-231 cells were obtained using the bio-
printing method, as previously described (Figueiredo et al., 2019), with 
some modifications. Briefly, MDA-MB-231 and human Foreskin fibro-
blast cell lines were seeded in 6-well plates at density of 4 × 105 cells per 
well and left to attach overnight. Afterwards, each well was treated with 
50 µL of NanoShuttle-PL (Nano3D Biosciences Inc., Germany) and 
incubated for 10 h. After incubation time, cells were washed with sterile 
PBS, detached by trypsin and mixed again to obtain a final number ratio 
of 8:2 for cancer cells and fibroblast, respectively. The cell mixture was 
then seeded in ultralow attachment 96-well plates at a density of 8 × 103 
cells per well and the resulting plate was placed on the top of 96-well 
spheroid magnetic drive for 15 h (Nano3D Biosciences Inc., Germany). 
Cells aggregated under a magnetic field and the resulting spheroids were 
cultured for 2 days before the treatment. 
2.9. In vitro cytotoxic studies 
The cytotoxic effects of DOX, with or without SRF, as free drugs and 
entrapped in bare or in LinTT1-functionalized liposomes, were evalu-
ated using 3D and 2D cellular models. 
For 2D cell models, MCF-7 and MDA-MB-231 breast cancer cell lines 
were used. Cells were placed in 96-well plates (8 × 103 cells per well) 
and allowed to attach overnight at 37 ◦C. The culture medium was then 
removed, replaced with medium containing therapeutic bare and 
LinTT1-functionalized liposomes, with a final DOX concentration from 
0.01 to 10 µM and incubated for 24, 48 and 72 h. Based on the relative 
drug loading percentage (%), the SRF concentration tested during the 
experiments, at different incubation times, was one third of the DOX. 
CellTiter-GloR® luminescence cell viability assay kit (Promega Corpo-
ration, USA) was used to calculate the cell viability percentage (%), 
according to the Equation (4). Luminescence was evaluated by Vari-





× 100 (4) 
where LumT is the luminescence associated to treated cells and Lumc 
is the luminescence associated to untreated cells (negative control). 
For 3D cell model, spheroids of MDA-MB-231 cells, obtained as 
described above, were gently transferred to 96-well plates (PerkinElmer 
Inc., USA) and the cell viability was evaluated by using a RealTime- 
Glo™ MT Cell Viability Assay. Briefly, DOX and SRF as free drugs or co- 
loaded into bare- and LinTT1-Lipo, were diluted in 50 µL of culture 
medium and mixed with 50 µL of cell culture medium containing 
NanoLuc luciferase and MT Cell Viability Substrate. Drugs, both in free 
form or co-loaded into liposomes, were tested at the same range of 
concentration that was used for 2D cell culture models. The analysis was 
carried out at different time points (6, 24, 48 and 72 h). The lumines-
cence was measured using a VarioskanTM LUX multimode microplate 
reader (Thermo Fisher Scientific Inc., USA), at different incubation 
times. The cell viability percentage (%) was calculated according to 
Equation (4). All the experiments for 2D and 3D cellular models were 
performed in triplicate, and results are expressed as the average ± S.D. 
2.10. 3D spheroids and liposomes interaction studies 
Interactions between 3D spheroids of MDA-MB-231 cells and lipo-
somes were quantitatively and qualitatively evaluated by flow cytom-
etry and confocal laser scanning microscopy, respectively. 3D spheroids 
of MDA-MB-231 cells were washed with fresh PBS and then incubated 
with culture medium containing fluorescent bare-Lipo or LinTT1-Lipo 
with a final lipid concentration of 500 µg mL− 1 for 3 and 6 h. 
For flow cytometry analysis, 3D spheroids of MDA-MB-231 cells 
were firstly incubated with fluorescent bare- and LinTT1-Lipo, and then, 
after suitable incubation times, were harvested for 5 min with trypsin- 
PBS-EDTA, collected by centrifugation at 1,500 RCF for 5 min and 
washed twice with PBS solution. The resulting cell suspension was 
incubated with trypan blue solution (0.005% v/v) for 4 min, then 
washed twice with PBS-EDTA and re-suspended with fresh PBS-EDTA. 
The analysis was carried out using LSR II flow cytometer (BD Bio-
sciences, USA), with FACS Diva software. At least 5,000 events were 
collected for each sample, and data was analyzed by FlowJo VX software 
(Tree Star, Ashland, OR, USA). All experiments were performed in 
triplicate. 
For confocal laser scanning microscopy analysis, 3D spheroids were 
treated with fluorescent bare- and LinTT1-Lipo, and then, after incu-
bation times, the cells were washed twice with PBS solution. 3D 
spheroids of MDA-MB-231 cells were fixed for 24 h at 37 ◦C using PFA 
(4% v/v). 3D spheroids of MDA-MB-231 cells were then washed with 
PBS solution and the nuclei were stained by adding of DAPI-405 (100 µL; 
2.8 µg mL− 1) and then incubated again for 24 h at 37 ◦C. Afterward, 3D 
spheroids of MDA-MB-231 cells were further washed twice with PBS and 
the localization of bare and LinTT1-functionalized liposomes was 
observed with a Leica SP5 inverted confocal microscope (Leica Micro-
systems, Germany), equipped with a 20 × objective. 
2.11. Isolation of CD14+ peripheral blood mononuclear cells (PBMC) 
from whole human blood and polarization of M2 macrophage 
Monocytes were isolated from the whole human blood and polarized 
in M2 macrophage, as reported elsewhere (Torrieri et al., 2020). Briefly, 
the whole human blood, collected from anonymous donors of the 
Finnish Red Cross Blood Service and used within 2 h, was diluted with 
an equal volume of PBS (10 mM, pH 7.4) at room temperature. About 20 
mL of diluted blood was layered over 15 mL of Ficoll®-Paque solution in 
a falcon tube to separate blood constituents through density gradient 
centrifugation at 400g for 40 min at room temperature. Afterward, RBCs 
were stored at 4 ◦C and used for hemocompatibility test, while the 
PBMCs (the middle layer on the interface between plasma and Ficoll 
solution) were transferred in new falcon tubes and washed with fresh 
PBS buffer. The supernatant was discarded, and the pelleted cells were 
re-suspended in 5 mL of magnetic-activated cell sorting (MACS) buffer. 
After counting, CD14+ monocytes were isolated from PBMCs by mag-
netic labeling using MAb CD14 conjugated microbeads (Miltenyi, 
Biotech, GmBH, USA), followed by physical separation through mag-
netic column, according to manufacturers’ instructions. CD14+ mono-
cytes obtained were seeded in a petri capsule at a density of 2 × 106 cells 
per 10 mL of Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 10% of FBS. To promote the differentiation in M2 
macrophage, RPMI medium was further supplemented with cytokines 
macrophage colony-stimulating factor (M− CSF) at the final concentra-
tion of 20 ng mL− 1. After three days the medium was removed and 
replaced with a fresh one with the same composition. At day 6 cells were 
washed twice, detached with PBS/EDTA solution (EDTA concentration 
5 mM), centrifuged at 500g for 5 min, re-suspended with RPMI medium, 
and seeded in 12-well plates at the density of 2.5 × 105 cells per well for 
flow cytometry analysis. For each well the medium was supplemented 
with 20 ng mL− 1 of interleukin 4 (IL-4). Three wells for each plate were 
supplemented only with 20 ng mL− 1 of M− CSF and were used as 
negative control during the analysis (MØ macrophages). On day 8, the 
markers expression was evaluated in order to confirm the macrophage 
differentiation. The successful polarization of M2 macrophages was 
evaluated by flow cytometer analysis using two different fluorescent 
human antibodies: allophycocyanin (APC)-CD86 and fluorescein iso-
thiocyanate (FITC)-CD206. The two antibodies were incubated with 
cells for 15 min at 4 ◦C, and then washed twice to remove the uncon-
jugated antibodies. The expression of two markers was evaluated 
through LSR II flow cytometer (BD Biosciences, USA). Analyses were 
performed in triplicate and MØ macrophages were used as control. 
Finally, at day 9, the interaction between human M2 macrophages and 
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bare and LinTT1-functionalized liposomes was evaluated. 
2.12. Human M2 macrophage-liposomes interaction studies 
Flow cytometry analysis was used to study the interaction between 
primary human macrophages, and bare and LinTT1-functionalized li-
posomes. Briefly, after polarization, M2 macrophages were seeded in 12- 
well plates at a density of 2 × 105 cells per well overnight. After 
removing the cell culture medium, the wells were washed once with PBS 
solution (pH 7.4). Then, 1.5 mL of bare and LinTT1-functionalized li-
posomes, with a final lipid concentration of 250 µg per well, were 
incubated with the cells for 1 and 3 h at 37 ◦C. Cells were washed twice 
with PBS solution and then harvested with PBS-EDTA solution. The 
resulting cell suspensions were centrifuged and washed with PBS buffer 
three times, and then pelleted cells were re-suspended in an appropriate 
volume of PBS-EDTA solution for flow cytometer analysis. The interac-
tion extent between liposomes (both bare- and LinTT1-Lipo) and M2 
macrophages were evaluated without and with trypan blue solution 
(0.005% v/v) that was used as cell membrane quencher agent during the 
experiments. When required, trypan blue solution was incubated with 
cell suspension for 4 min and then washed twice with PBS-EDTA solu-
tion. The analysis was performed with an LSR II flow cytometer (BD 
Biosciences, USA). Data were analyzed using Flowjo VX software (Tree 
Star, Ashland, OR, USA). 
2.13. Statistical analysis 
One-way analysis of variance (ANOVA), followed by Tukey’s mul-
tiple comparison test was used to analyze the significant difference 
among results. The analysis was carried out using SigmaPlot v.12 and 
Excel (Office 2010). Probabilities were set at three different significance 
levels: *p < 0.05; **p < 0.01 and ***p < 0.001. 
3. Results and discussion 
3.1. Physicochemical characterization 
Physicochemical properties, such as size, zeta-potential and size 
distribution play a crucial role to design DDSs, particularly on colloidal 
nanoparticles suitable for a potential systemic administration (Zhao 
et al., 2019). In this investigation, we analyzed the physicochemical 
properties of LinTT1-Lipo using dynamic light scattering technique. The 
average diameter of bare-Lipo and LinTT1-Lipo were 121 ± 3 nm and 
146 ± 4 nm, respectively. The increased hydrodynamic radius of 
LinTT1-Lipo depends on the presence of an additional hydrophilic 
molecule (LinTT1 peptide) conjugated onto the surface of liposomes 
(Fig. 1A) (Paolino et al., 2014). LinTT1 peptide also increased the zeta- 
potential value of liposomes changing from − 49.4 ± 3.1 (bare-Lipo) to 
–32.6 ± 2.3 mV (LinTT1-Lipo) (Fig. 1A). Differences on zeta-potential 
values between bare and functionalized liposomes may depend on the 
cationic aminoacids, i.e. arginine and lysine, present on the peptide’s 
structure. The presence of a guanidinium group and an additional amino 
group in arginine and lysine backbone, respectively, may provide a 
slight positive zeta-potential value to the free peptide, increasing the 
overall zeta-potential value of nanosystem after peptide’s conjugation to 
the liposomal surface. Conversely, there was no significant modification 
of the polydispersity index (PDI) between bare-Lipo and LinTT1-Lipo, 
having a narrow size distribution with a PDI<0.2 for both formula-
tions (Wolfram et al., 2014a) (Fig. 1A). This is in agreement with data 
previously reported elsewhere, that demonstrated for other types of 
nonosystems, a similar PDI before and after functionalization with 
LinTT1 peptide (Simón-Gracia et al., 2018b). Moreover, the ganglioside 
Fig. 1. Physicochemical properties of liposomes evaluated before and after conjugation of LinTT1. (A) Average hydrodynamic diameter, PDI, and zeta-potential 
value (ζ). (B) ATR-FTIR spectra of bare and LinTT1-functionalized liposomes. (C) Nitrogen amount quantification by elemental analysis of liposomes. (D) Fluo-
rescent intensity of bare and LinTT1-functionalized liposomes. Results are the average of three independent experiments ± standard deviation (S.D.). Statistical 
significance was obtained by a *p < 0.05, **p < 0.01, and ***p < 0.001. 
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was used to synthesize liposomal formulations in order to reduce the 
potential immunogenicity of PEG (d’Avanzo et al., 2020; Mima et al., 
2017). Indeed, despite this study is focused on in vitro analysis, nano-
vesicles were optimized for a potential in vivo application. Based on this 
evidence, ganglioside was used to make liposomes and data demon-
strated that the presence of this molecule in liposomal structure did not 
modify the stability of nanovesicles in vitro. 
Attenuated total reflectance − Fourier transform infrared (ATR- 
FTIR) analysis demonstrated a more intense carboxylic acid-indicative 
band at 1745 cm− 1 (carboxylic acid C = O stretching) in LinTT1-Lipo 
than bare-Lipo, thus suggesting the presence of a greater number of 
carboxylic groups on liposomes’ surface, after peptide’s conjugation. 
Moreover, the absence of the specific thiol-indicative band at 
2550–2600 cm− 1 (S-H stretching) in both formulations evidenced the 
lack of free thiolic groups in LinTT1-Lipo, hence confirming the reaction 
between thiolic group of cysteine in the peptide structure and the mal-
eimide group of polyglycol ethylene (PEG) residual. Nevertheless, in 
agreement with data reported elsewhere (Torrieri et al., 2020) for 
LinTT1-functionalized dextran nanoparticles, the conjugation of LinTT1 
peptide to the liposomal surface did not significantly modify the FTIR 
spectrum (Fig. 1B), making it necessary the use of further techniques to 
confirm the peptide conjugation. 
For this, the conjugation of LinTT1 on the surface of liposomes was 
further studied using elemental composition analysis, which showed a 
significant increase of the nitrogen amount in LinTT1-Lipo compared to 
bare-Lipo (Fig. 1C). This finding demonstrated that LinTT1 was suc-
cessfully conjugated onto the liposomes’ surface due to the large number 
of nitrogen atoms found in the peptide structure. Furthermore, in 
response to the presence of carboxy-fluorescein group (FAM) in the 
peptide structure, LinTT1-Lipo showed fluorescent properties (Fig. 1D). 
The resulting LinTT1-functionalized liposomes had a final peptide 
amount of 2.59 × 104 peptides/liposomes which corresponds to a den-
sity of ~ 0.66 peptide molecules/nm2. The resulting peptide density, 
which has been reported as number of peptide molecules/nm2 of lipo-
somal surface, was very similar to data published by Simón-Gracia in a 
previous work (0.7 peptide molecules/nm2 for LinTT1-funtionalized 
polymersomes), thus showing that LinTT1 peptide molecules is pre-
sent on liposomal surface and this amount of peptide can provide a 
specific targeting of resulting nanosystems versus biological models 
(Simón-Gracia et al., 2018b). These values were obtained starting from a 
liposomal concentration of 1.29 × 1012 nanovesicles/mL, and the final 
amount of conjugated LinTT1peptide (5.7 × 1016 peptide molecules/mL 
of final formulation) as reported in the Supplementary materials 
(Figure S1). 
The conjugation between LinTT1 and DSPE-PEG2000mal by 
sulfhydryl-maleimide reaction caused the synthesis of DSPE-PEG2000- 
LinTT1. The reaction between maleimide group of DSPE-PEG2000 and 
sulfhydryl of LinTT1 form a stable synthetic derivative. The synthesis 
success was confirmed by 1H NMR spectra of LinTT1, DSPE-PEGmal and 
DSPE-PEG2000-LinTT1. 1H NMR of LinTT1, DSPE-PEG2000mal and 
DSPE-PEGmal-LinTT1 showed that the characteristic maleimide sharp 
peak at 7 ppm was present in the spectrum of DSPE-PEG2000mal, but 
not in that of DSPE-PEG2000-LinTT1, confirming the happened reaction 
(Figure S4). These results agree with data previously reported for a 
similar reaction process (Wang et al, 2019). 
DOX, alone or in combination with SRF, was loaded in LinTT1-Lipo 
and tested in vitro, as described subsequently. Physicochemical charac-
terization of therapeutic liposomes demonstrated that the hydrody-
namic diameter of DOX-loaded liposomes (alone or in association with 
SRF) increased around 10 nm in comparison with empty ones, however 
no significant changes were found for the PDI and zeta-potential values 
(Table S1). Similar values of zeta-potential of empty and drugs-loaded 
nanovesicles demonstrated that DOX and SRF were entrapped inside 
the aqueous core and in the phospholipid bilayer of liposomes, respec-
tively, and they were not adsorbed on nanovesicles’ surface. The slight 
increase of average sizes of DOX-loaded liposomes can be ascribed to the 
DOX crystallization in the aqueous core of liposomes, as previously re-
ported (Pasut et al., 2015). TEM analysis showed that liposomes have 
spherical-like shapes and their shape is not modified by the conjugation 
of LinTT1 on the surface of nanocarriers (Figures S2 and S3). All drug- 
loaded liposomes, both functionalized and bare ones, exhibited the 
physicochemical characteristics suitable for their systemic use as drug 
delivery systems for anticancer therapy: (i) an average diameter below 
than 200 nm suggesting their ability to penetrate intact through fenes-
trated vasculature of neo-formed tumor vessels and accumulate in tumor 
tissue (Maruyama, 2011; Blanco et al., 2015); (ii) a net negative charge 
suggesting colloidal stability of nanosuspension (Di Francesco et al., 
2017a,b); and (iii) a PDI below than 0.2 showing a narrow size distri-
bution of nanovesicles (Vakili-Ghartavol et al., 2020) 
3.2. Hemocompatibility test 
Erythrocytes are the main cells in the bloodstream and closely 
interact with nanomedicines after their intravenous injections (Pretini 
et al., 2019), suggesting that the hemocompatibility of a potential sys-
temic nanoparticle needs to be investigated during the early stages of its 
development (de la Harpe et al., 2019). In this scenario, the hemo-
compatibility of LinTT1-Lipo was investigated and their incubation with 
human RBCs demonstrated that the conjugation of LinTT1 peptide on 
the surface of liposomes via PEG does not lead to a hemolytic nano-
system. LinTT1-Lipo induced a hemolysis percentage below than 2% for 
all tested lipid concentrations up to 48 h of incubation (Fig. 2), which is 
lower than the threshold of 5% fixed by ISO/TR 7405–1984 for hemo-
lytic samples (Zhang et al., 2018). Results demonstrated that LinTT1- 
Lipo are safe and biocompatible and do not cause hemolysis of human 
RBCs, suggesting their suitable use for intravenous administration. 
3.3. Drugs loading and in vitro release kinetic profiles of payloads 
Multidrug liposomes were obtained by co-loading of SRF and DOX 
inside the liposomes based on their physicochemical properties and 
solubility (Xiao et al., 2016; Cai et al., 2014), and the relative entrap-
ment efficiency (E.E.%) and drug loading (L.D.%) were evaluated using 
the proper calibration curve Equations (Figure S5). SRF, which is co- 
loaded in the bilayer of therapeutic liposomes, did not affect the high 
E.E. of DOX in the aqueous compartment. DOX-loaded liposomes, with 
Fig. 2. Hemocompatibility of LinTT1-functionalized liposomes. Hemolysis was 
monitored up to 48 h of incubation with human erythrocytes at 37 ◦C. Different 
lipid concentrations (25, 50, 100, and 200 µg mL− 1) were tested during the 
analysis. Lysed hemoglobin was quantified in the supernatant at the wavelength 
of 577 nm using a UV–Vis spectrophotometer. Results are the average of three 
independent analysis ± S.D. 
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or without SRF, showed an E.E. of around 90% and a L.D. of 4.5% 
(Table S1). High E.E. of DOX inside the therapeutic liposomes depended 
on the crystallized drug that precipitates inside the aqueous core of li-
posomes, thus forming a gel-like structure as a consequence of trans-
membrane pH gradient and remote loading procedures that were used 
for the liposomes’ preparation (Cheung and Al-Jamal, 2019; Fritze et al., 
2006). Conversely, the E.E. and L.D. efficiencies of SRF-loaded lipo-
somes were around 50% and 1.25%, respectively (Table S1). In partic-
ular, the co-loading of both drugs into the LinTT1-Lipo resulted in a 
slight reduction of E.E. of SRF from 51.6 ± 1.1 to 49.8 ± 0.4, while no- 
significant changes were observed for DOX (Table S1). These results 
were in agreement with data previously published for liposomes con-
taining gemcitabine and paclitaxel in the same colloidal nanocarrier and 
the very slight decrease or the absence of significant changes in the 
drugs loading capacity could be explained by the different compartment 
localization of the two bioactive compounds (Cosco et al., 2011). 
Moreover, the entrapment and drug loading efficiencies for both drugs 
were very similar between bare-Lipo and LinTT1-Lipo, suggesting that 
the surface architecture of liposomes did not affect these parameters 
(Table S1). 
The release kinetics of DOX and SRF from LinTT1-Lipo/D + S were 
evaluated into two different receptor media: PBS supplemented with 
FBS (10% v/v) and PBS supplemented with Tween 80 (Tw80) (1% v/v). 
The receptor media were chosen based on media previously reported 
elsewhere (Tahir et al., 2020; Guo et al., 2017) for the SRF release study. 
The analysis was performed at physiological pH and in acid condition 
(pH 5.5 and pH 6.5) in order to mimic the TME (Justus et al., 2013). 
Around 25% of DOX was released after 72 h of incubation in the medium 
supplemented with FBS and ≈30% of drug in the receptor medium 
supplemented with Tw80. No significant difference was observed for the 
cumulative release of DOX in the media that have different pH, thus 
having similar results after 72 h of incubation (Fig. 3). In particular, only 
slight differences were observed in the release profile of DOX after 3 h of 
incubation between physiological pH and pH = 5.5. These results 
demonstrated that the release kinetic of DOX from LinTT1-Lipo/D + S 
was independent of the pH of selected receptor media. This is in 
agreement with data previously reported elsewhere that demonstrated a 
similar kinetic release of DOX from PEGylated liposomes in PBS solution 
at pH 5.5 and 7.4 (Shibata et al., 2015). The lack of significant variations 
in the cumulative release of DOX at different tested pH-values could 
depend on the ammonium sulfate, and particularly the sulfate, used to 
generate the pH gradient during the remote loading procedures. In fact, 
sulfate is a base conjugate obtained after dissociation of strong acid, and 
the slight decrease of pH from 7.4 to only 5.5 does not allow its pro-
tonation, thus resulting in a massive interaction of negative sulfate with 
protonated DOX at specific pH range (from 5.5 to 7.4) used during the 
study as previously reported (Fritze et al., 2006). This property affects 
similar results obtained for the release kinetic of DOX at different pH- 
values (Fritze et al., 2006). Conversely, 10 ± 2% of SRF was released 
at pH 5.5 for both receptor media, while 12 ± 2% and 28 ± 4% of drug 
was released at pH 7.4 for receptor medium supplemented with FBS and 
Tw80, respectively (Fig. 3). Instead, the cumulative release of SRF at pH 
6.5 was 17 ± 3% and 10 ± 1% in the medium supplemented with Tw80 
and FBS, respectively, after 72 h of incubation. 
Therefore, the release of SRF in the medium with Tw80 at pH 7.4 was 
twice that of the drug released in medium supplemented with FBS at the 
same pH (28 ± 4% for Tw80 versus 12 ± 2% for FBS). This difference 
needs more investigations, but probably the higher release of SRF in the 
receptor medium containing Tw 80 at pH 7.4 in comparison with pH 5.5 
may depend on the lower critical micelle concentration (CMC) of this 
surfactant at physiological pH than the acid one, as previously demon-
strated elsewhere (Bloor et al., 1970) for Tween 40 (Tw40) that have the 
same hydrophilic head of Tw80 and differs only for the acyl chain. This 
hypothesis is further supported by release data obtained at pH 6.5. 
Indeed, despite the SRF released in the medium supplemented with 
Tw80 is higher than that obtained for the medium supplemented with 
Fig. 3. Release kinetic of DOX and SRF from LinTT1-functionalized liposomes in two different media at pH 7.4 (A), pH 6.5 (B) and pH 5.5 (C), at 37 ◦C. The amount 
of released drugs was calculated by using external calibration curves as reported in Figure S7 and S8 of Supplementary material. Results are the average of three 
independent experiments ± S.D. Error bars, if not shown, are within symbols. 
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FBS after 72 h (17 ± 3% vs. 10 ± 1%, respectively), this difference was 
significantly lower than results obtained at physiological pH, thus 
showing that pH-value can affect the SRF release kinetic of LinTT1- 
liposomes in the accepting medium supplemented with Tw80. 
Moreover, Tw80 is a non-ionic surfactant that can be adsorbed on the 
external surface of liposomal bilayer, thus making mixed micelles with 
lipids of liposomes, as previously reported for other lipids (Paolino et al., 
2017). This complex can favor strong interaction between Tw80 and SRF 
diffused across lipid bilayer resulting in the leakage of liposomes su-
pramolecular structure. This may increase the solubility of SRF and its 
release in the medium supplemented with Tw80, especially at pH 7.4, 
where the lower CMC of this surfactant improves its solubilizing 
properties. 
Release kinetic of SRF and DOX in different experimental conditions 
have a biphasic release kinetic with rapid and continuous release 
following a zero-order kinetic up to 12 h of incubation, and a plateau 
from 24 to 72 h of incubation (Fig. 3). Results showed that LinTT1-Lipo 
were able to co-deliver continuously DOX and SRF up to 72 h in phys-
iological and acid media without a massive and rapid release of pay-
loads. These findings showed a sustained drugs release from 
functionalized liposomes, suggesting the ability of this nanosystem to 
avoid the rapid cargo leakage, thus potentially reducing the side effects 
of delivered chemotherapeutic agents (Bozzuto and Molinari, 2015). In 
particular, DOX crystallization hampered the quick leakage of drug after 
in vitro and in vivo use and significantly increased the encapsulation 
efficiency of doxorubicin hydrochloride in the aqueous core of lipo-
somes. This is a direct effect of drug-gel-like structure occurred in the 
aqueous core of liposomes using pH-gradient and remote procedure as 
previously reported for Doxil/Caelyx (Barenholz, 2012) and depend on 
different physicochemical parameters that are specific for drug candi-
dates (Cern et al., 2014; Cern et al., 2017). 
However, the gel-like structure resulted by crystallizing doxorubicin 
hydrochloride and the resulting slow and constant drug release did not 
affect and/or decrease the anticancer efficacy of payload and its cyto-
toxicity on breast cancer cells. In fact, LinTT1-liposomes can be targeted 
from breast cancer cells overexpressing LinTT1 specific receptors and 
colloidal nanocarriers were like a depot system, which favored the 
accumulation of crystallized doxorubicin hydrochloride inside the can-
cer cells and provided the slow dissolution of payload in the intracellular 
compartment, as reported elsewhere (Li et al., 2019; Wei et al., 2015). 
Based on these, the therapeutic effects of drugs were not compro-
mised in vivo due to the biodegradable properties of liposomes that are 
degraded after internalization in tumor tissues and then release payloads 
(Costanzo et al., 2019). 
3.4. Stability studies in human plasma 
Nanomedicines should remain stable after systemic injection and 
biomaterials making polymeric shell or lipid bilayer were selected to 
protect nanocarriers from destabilization phenomenon occurring after 
interaction with plasma proteins (Immordino et al., 2006). Nanocarriers 
injected in vivo interact with circulating cells and proteins and these 
phenomena may cause several mechanical stresses and activate enzy-
matic processes (Di Francesco et al, 2021). These drawbacks can 
strongly decrease the therapeutic effect of nanomedicines, thus causing 
degradation of nanocarriers, with the quick leakage of payloads, or their 
rapid clearance from bloodstream and significant macrophage uptake 
(Ferrari, 2010). Circulating serum proteins play a crucial role for the 
potential modification of surface properties in nanocarriers, and thus, 
their destabilization after systemic injection (Pasut et al., 2015), due to 
protein corona phenomenon (Palchetti et al., 2016). Protein corona 
significantly modifies the physicochemical properties of nanocarriers, 
thus increasing average sizes and size distribution, as well as their sur-
face properties and compositions (Hadjidemetriou et al., 2019). Protein 
corona phenomenon can also facilitate the macrophage uptake of 
nanocarriers, and thus, their clearance through the reticuloendothelial 
system (RES) organs (Monopoli et al., 2012). In these attempts, we 
studied the stability of LinTT1-lipo + D/S after incubation with human 
plasma and the resulting data was compared that obtained for Caelyx- 
like Lipo (control), which is similar to Doxil/Caelyx liposomal formu-
lations currently approved from Food and Drug Administration and 
European Medicine Agency for the treatment of breast cancer (Monopoli 
et al., 2012, Bulbake et al., 2017). LinTT1-lipo + D/S and Caelyx-like 
Lipo had similar trend for average sizes after 72 h of incubation in 
human plasma (Fig. 4). They showed a slight decrease of particle sizes 
(~15 nm) in the 1 h of incubation, maybe due to the adsorption of a 
weak protein corona on the surface of PEGylated liposomes. This process 
resulted in an osmotic gradient on liposomal surface leading to the 
shrinkage of nanocarriers, and thus, the leakage of water content from 
the aqueous core of liposomes (Wolfram et al., 2014b). Conversely, the 
average sizes of LinTT1-lipo + D/S and Caelyx-like Lipo increased after 
48 h of incubation and this phenomenon increased significantly after 72 
h of incubation with resulting average sizes of ~ 230 nm and ~ 180 nm 
for LinTT1-Lipo + D/S and Caelyx-like Lipo (Fig. 4), respectively. The 
significant increase of particle sizes at 48 and 72 h of incubation, may 
depend on a biphasic process occurring during the formation of protein 
corona on nanocarriers surface. In fact, we can hypothesize that during 
the early stages of incubation, proteins having high concentrations but 
low affinity for liposomal bilayer, formed an unstable protein corona, 
which is in equilibrium and exchanges with the surface of liposomes 
without changing significantly particle sizes. Conversely, at long incu-
bation times (48 and 72 h), circulating proteins, making protein corona, 
had a low concentration but high affinity for liposomes. The high affinity 
protein corona for liposomal surface replaced soft corona, adsorbed at 
short incubation times, with hard corona that stack to the surface of 
nanocarriers and thus increased their average size (Pozzi et al., 2015; 
Wolfram et al., 2014b). The resulting data also demonstrated that 
LinTT1-lipo + D/S and Caelyx-like Lipo were stable and did not change 
their average sizes up to 24 h (Fig. 4). The stability tests supported our 
hypothesis that LinTT1-Lipo + D/S is stable in human plasma and 
circulating proteins do not affect nanocarrier stability, and fostered a 
potential in vivo translation of LinTT1-Lipo + D/S. 
Despite, the significant increment of particle size after 72 h of in-
cubation with human plasma, average sizes of Caelix-like Lipo and 
LinTT1-Lipo + D/S were less than twice compared to the initial data 
(~112 nm (Caelix-like Lipo) and ~ 160 nm (LinTT1-Lipo + D/S) at time 
point 0 vs. ~ 180 nm (Caelix-like Lipo) and ~ 230 nm (LinTT1-Lipo + D/ 
S) at 72 h), thus supporting the hypothesis that nanocarriers did not 
make aggregates after 72 h of incubation in human plasma, but the 
Fig. 4. Human plasma stability of LinTT1-Lipo + D/S and Caelyx-like Lipo. 
Results are the average of three independent experiments ± S.D. (n = 3). Error 
bars, if not shown, are within symbols. 
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increase of sizes depended on the resulting protein corona adsorbed on 
the surface of liposomes (Pozzi et al., 2015; Wolfram et al., 2014b). Our 
hypothesis was further supported by Turbiscan analysis, which 
demonstrated the lack of aggregation for LinTT1-Lipo + D/S and Caelix- 
like Lipo in saline solution (NaCl) 0.9%, w/v, (Figure S9) and medium 
(saline solution NaCl 0.9%/human plasma, 50:50 (v/v)) (Figure S10) at 
37 ◦C. LinTT1-Lipo + D/S and Caelix-like Lipo had BS and T signal 
variations below 5% and 10% during the incubation time (1 h) and their 
relative lines were overlapped with the threshold baseline (Di Francesco 
et al., 2017a,b). The presence of negative or positive peak variations for 
BS and T signals at samples height over 8 mm and below 2 mm did not 
depend on the nanocarrier destabilization but was related to air bubbles 
present at the interfaces on the top or bottom of glass holder during the 
analysis (Celia et al., 2009). The long-term stability of LinTT1-Lipo + D/ 
S and Caelix-like Lipo in human plasma were further confirmed by 
destabilization kinetic profiles which were similar for both nanocarriers 
(Figure S11). These results were in agreement with data herein reported 
for DLS analysis (Fig. 4), and thus, demonstrate that LinTT1-Lipo + D/S 
is stable and has suitable physicochemical properties for a potential 
injection in the bloodstream. 
3.5. In vitro cytotoxic effect on 2D cell models 
DOX, as a free drug or formulated as PEGylated liposomes, is 
currently one of the most used chemotherapeutic drugs to treat breast 
cancers, and particularly TNB cancer (Waks and Winer, 2019). DOX is 
usually administereted in combination with other cytotoxic drugs, such 
as paclitaxel and cyclophosphamide (Waks and Winer, 2019; Tampaki 
et al., 2018), and these combinations have a synergistic effect that re-
sults in a decreased effective dosage of drugs compared to mono-therapy 
(Fisusi and Akala, 2019). This approach decreases the side effects and 
modifies the induction rate of cancer resistant phenomena (Waks and 
Winer, 2019; Yardley, 2013). Despite controversial results about the use 
of SRF in combination with other chemotherapeutic agents in breast 
cancer therapies, some clinical trials are still ongoing (Chen et al., 
2019a; Hwang et al., 2019). Moreover, several animal investigations 
have clearly shown the ability of SRF to increase the anticancer prop-
erties of chemotherapic agents commonly used in clinic for breast cancer 
therapies, especially when the two drugs were co-loaded in the same 
nanocarriers. In these attempts, Sui et al. recently demonstrated the 
higher anticancer efficacy of SRF-loaded into pullulan-DOX conjugated 
nanoparticle than the same nanosystem containing only DOX, on murine 
breast cancer carcinoma (Sui et al., 2017). In this study, they also 
showed a great reduction of side effects when the two drugs were co- 
loaded into nanoparticles than the combination of free drugs adminis-
tered in the free form. Similar results were also observed by Lei et al., 
which demonstrated a great synergistic effect of SRF and paclitaxel 
when the two drugs were co-loaded into the same liposomal carrier, on 
MCF-7/multidrug resistant cancer in mice (Lei et al., 2019). 
In our study, the capability of SRF to potentiate the cytotoxic effect of 
DOX was tested in two different breast cancer cell lines. In particular, a 
positive estrogen receptor (MCF-7) and a triple negative (MDA-MB-231) 
breast cancer cell lines were used during the study. The cytotoxic effect 
was evaluated based on drug concentrations (0.01–10 µM) and incu-
bation times (24, 48 and 72 h). Drug concentration, for the in vitro tests, 
is reported as a ratio to the DOX concentration, which is three-fold 
higher than SRF at different incubation time points. This difference 
depends on the final concentration of DOX and SRF, which are co-loaded 
inside liposomes, being 1600 and 540 µM for DOX and SRF, respectively. 
As the first step, the cytotoxic effect of DOX as a single agent was 
compared with the cytotoxic effect provided by the association of SRF 
and DOX, both in free form or loaded in bare liposomes (Fig. 5). The 
cytotoxic effect of SRF as a single agent was not investigated in this 
study, because despite its potential ability to increase the efficacy of 
breast cancer therapies when it is co-administered with other chemo-
therapeutics, its efficacy as single agent has been demonstrated to be 
poor in breast cancer (Bronte et al., 2017). 
SRF significantly increased the cytotoxic effects of DOX when the 
two drugs were co-loaded in bare liposomes in positive estrogen re-
ceptors (MCF-7) and in TNB cancer (MDA-MB-231) cell lines, compared 
to free drugs (Fig. 5). 
This effect was similar in MCF-7 and MDA-MB-231 cells. In partic-
ular, after 24 h of incubation, the cytotoxic effect of free DOX and 
combined free DOX and SRF was very similar for all drug concentrations 
in both investigated cell lines. On the contrary, at the same incubation 
time point, the cytotoxic effect of DOX and SRF co-loaded in bare lipo-
somes (bare-Lipo/D + S) was significantly higher than bare liposomes 
containing only DOX (bare-Lipo/D), at the DOX concentration of 0.5 and 
1 µM, and SRF concentration equivalent to 0.17 and 0.35 µM, respec-
tively. The ability of SRF to improve the cytotoxic effect of DOX when 
the two drugs were co-loaded in bare liposomes in comparison with free 
drugs, became more evident after 48 and 72 h of incubation (Fig. 5). 
After 48 h of incubation, bare-Lipo/D + S showed a cell death of 45.8 ±
2.9% and 60.0 ± 3.6% on MCF-7 cell line at the DOX concentration of 
0.5 µM (and SRF concentration equivalent to 0.17 µM) and at DOX 
concentration of 1 µM (and SRF concentration equivalent to 0.35 µM), 
respectively; while bare-Lipo/D demonstrated a cell death of 32.2 ±
4.5% and 44.3 ± 3.1% at the same DOX concentrations, respectively. 
Furthermore, the association of free drugs resulted in a slight reduction 
of cell viability compared with free DOX. After 48 h of incubation, MCF- 
7 cells showed a cell death of 27.7 ± 4.9% and 38.3 ± 3.6% when treated 
with combined drugs at DOX concentration of 0.5 µM (and SRF con-
centration equivalent to 0.17 µM) and at DOX concentration of 1 µM 
(and SRF concentration equivalent to 0.35 µM), respectively; and 22.5 ±
2.9% and 30.6 ± 4.8% for free DOX as single agent at the same DOX 
concentrations, respectively. Similar trend was observed in MDA-MB- 
231 cells after 48 h of incubation with bare-Lipo/D, showing a cell 
death of 44.5 ± 2.1% at DOX concentration of 0.5 µM, while cell treated 
with bare-Lipo/D + S showed a cell death of 58.1 ± 4.4% at the same 
DOX concentration and SRF equivalent concentration of 0.17 µM. Also, 
in this cell line, the cytotoxic synergistic effect of combined free drugs 
was lower than DOX and SRF co-loaded liposomes. Indeed, after 48 h of 
incubation, the cell death was 32.8 ± 5.9% at DOX concentration of 0.5 
and 39.9 ± 6.3% at the same DOX concentration (and SRF concentration 
equivalent to 0.17 µM), for free DOX and combined free drugs, 
respectively. 
Moreover, after 72 h of incubation with bare-Lipo/D + S the cell 
death was of 59.2 ± 5.9% and 74.2 ± 4.6% at DOX concentration of 0.5 
µM (and SRF concentration equivalent to 0.17 µM), for MCF-7 and MDA- 
MB-231 cell line, respectively (Fig. 5). Conversely, combinations of free 
drugs had a similar cytotoxic effect herein reported (61.5 ± 3.6% and 
68.2 ± 5.2%) at DOX concentration equivalent to 1 µM (and SRF con-
centration equivalent to 0.35 µM), for MCF-7 and MDA-MB-231 cell 
lines, respectively (Fig. 5). This effect highlighted the potentiality of 
liposomes to decrease the therapeutic drugs dosage for efficacious 
treatment in breast cancer (Meng et al., 2016). 
The increased cytotoxic efficacy of bare-Lipo/D + S in comparison 
with the association of free drugs was probably due to the enhanced 
synergistic effect of the two chemotherapeutic drugs in response to their 
allocation in the same nanovesicle, which provided an increased uptake 
from breast cancer cells and reduced destabilization phenomena on 
drugs molecules (Sercombe et al., 2015). Based on these findings, for 
further analysis concerning the cytotoxic efficacy, liposomes containing 
both drugs were used. The cytotoxic effect of DOX and SRF, as free drugs 
or formulated as liposomes, was always higher in MDA-MB-231 cells 
than MCF-7 cells. This difference depends on the higher responsiveness 
of MDA-MB-231 cells than MCF-7 ones to DOX (Lovitt et al., 2018). 
One of the main challenges in anticancer therapies is to target spe-
cifically the pathological tissues, improving the efficacy of therapy and 
decreasing side effects on healthy cells (Yan et al., 2020; Pu et al., 2019). 
In these attempts, we functionalized liposomes by conjugating onto the 
surface of liposomes via PEG the LinTT1 peptide, a specific ligand for 
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p32 receptor that is overexpressed on cytoplasmic membrane by several 
breast cancer cell lines (Fogal et al., 2008; Simón-Gracia et al., 2018b). 
The cytotoxic effect of LinTT1-Lipo/D + S liposomes was evaluated in 
vitro using MCF-7 cells and MDA-MB-231 cells. The anticancer activity 
of LinTT1-Lipo/D + S was compared to bare-Lipo/D + S (Fig. 6). 
LinTT1-Lipo/D + S increased the cytotoxic effect of payloads on MCF-7 
cells and MDA-MB-231 cells compared to bare-Lipo/D + S (Fig. 6). 
In particular, the conjugation of LinTT1 onto the surface of thera-
peutic liposomes increased significantly the anticancer activity in 2D 
cell models of MCF-7 and MDA-MB-231 breast cancer cells at shorter 
incubation time (24 h) than longer ones (48 and 72 h) (Fig. 6). These 
differences may depend on the static experimental conditions of the 
analysis that forced the interactions between liposomes and cells and the 
resulting uptake of nanovesicles, thus suppressing or greatly reducing 
differences between LinTT1-Lipo/D + S and bare-Lipo/D + S at long 
incubation times. This phenomenon does not reflect the physiological 
conditions occurring in vivo, where “washing properties” of blood stream 
and the solid cancer 3D architecture decrease the contact between 
nanoparticles and cell surface (Palange et al., 2014). 
The cell death percentage (%) at DOX concentration of 0.1 µM and 
SRF corresponding concentration of 0.035 µM was 14.8 ± 4.0% and 
29.2 ± 3.6%, respectively, for bare-Lipo/D + S and LinTT1-Lipo/D + S 
after 24 h of incubation on MCF-7 cells (Fig. 6A). Similar results were 
also obtained for MDA-MB-231 cells, where LinTT1-Lipo/D + S had a 
cell death percentage (%) of 40.1 ± 3.7% compared to bare-Lipo/D + S 
(19.8 ± 4.4%) after 24 h of incubation, at the same drug concentrations 
(Fig. 6B). Moreover, LinTT1-Lipo/D + S provided a higher cell death 
than bare-Lipo/D + S for all drug concentrations investigated after 24 h 
of incubation, on both cell lines (Fig. 6). Furthermore, less significant (or 
no significant) differences were observed between LinTT1-Lipo/D + S 
and bare-Lipo/D + S after 48 and 72 h of incubation. At the DOX con-
centration of 0.1 µM and SRF corresponding concentration of 0.035 µM, 
the cell viability of MCF-7 cells was 70.2 ± 4.6% and 64.8 ± 4.0% when 
treated with bare-Lipo/D + S and LinTT1-Lipo/D + S, respectively, after 
48 h of incubation. Significant differences between the two formulations 
were observed in this cell line only at DOX concentration of 0.5 µM and 
SRF corresponding concentration of 0.17 µM, and at DOX concentration 
of 10 µM and SRF corresponding concentration of 3.5 µM, after 48 h of 
incubation. These differences were still significantly lower than the ones 
observed on the same cell line at the same drugs concentration after 24 h 
of incubation. Similar trend was observed after 72 h of incubation, 
where only at the two lowest drugs concentration significant differences 
were found between bare-Lipo/D + S and LinTT1-Lipo/D + S, on MCF-7 
cells. In particular, at DOX concentration of 0.01 µM and SRF corre-
sponding concentration of 0.0035 µM, this cell line showed a cell 
viability of 79.6 ± 5.6% and 70.4 ± 3.2%, for bare-Lipo/D + S and 
LinTT1-Lipo/D + S, respectively, after 72 h of incubation; while it 
showed a cell viability of 58.1 ± 3.4% and 51.3 ± 4.0% for bare-Lipo/D 
+ S and LinTT1-Lipo/D + S, respectively, at the DOX concentration of 
0.1 µM and SRF corresponding concentration of 0.035 µM, at the same 
incubation time point. Similar results were obtained on MDA-MB-231 
cells that demonstrated less significant (or no-significant) differences 
of cell viability between bare-Lipo/D + S and LinTT1-Lipo/D + S for 
almost all drugs concentrations after 48 and 72 h, compared to 24 h of 
incubation. Moreover, in this cell line, LinTT1-Lipo/D + S provided a 
higher cytotoxic efficacy than bare-Lipo/D + S only at DOX concentra-
tion of 0.01, 0.1 and 1 µM and SRF corresponding concentration of 
0.0035, 0.035 and 0.35 µM, respectively, after 48 h of incubation; and at 
DOX concentration of 0.01, 0.1 µM and SRF corresponding concentra-
tion of 0.0035, 0.035, respectively, after 72 h of incubation. When 
Fig. 5. In vitro cytotoxic activity of DOX, as single agent or combined with SRF, in free form or loaded into liposomes on MCF-7 (Panel A) and MDA-MB-231 (Panel B) 
cell lines using a 2D breast cell culture model. Cytotoxic effect was reported as cell viability percentage (%) and evaluated as a function of incubation times and drug 
concentrations. Cellular viability percentage (%) was evaluated by using CellTiter-Glo luminescence assay. Results are the average of at least three independent 
experiments ± S.D. Statistical significance was set at: *p < 0.05, **p < 0.01, and ***p < 0.001. Cell viability (%) of cells treated with empty liposomes was always 
over than 90% for all tested concentration and incubation time points (data not shown). Error bars, if not shown, are within symbols. 
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significant, the differences between bare-Lipo/D + S and LinTT1-Lipo/ 
D + S after 48 and 72 h of incubation were still less significant than the 
ones observed after 24 h of incubation at the same drugs concentrations. 
These results demonstrate that the functionalization of the liposomes’ 
surface with LinTT1 peptide increased the cytotoxic effect of therapeutic 
liposomes on MCF-7 and MDA-MB-231 breast cancer cell lines compared 
to bare therapeutic liposomes, especially after low incubation time 
point. These findings suggest that the conjugation of this ligand on 
therapeutic liposomes’ surface promoted the interaction rate and 
cellular uptake of nanovesicles on both investigated cell lines. 
3.6. In vitro cytotoxic effect on 3D spheroid cell models 
3D spheroids of breast cancer cells were created to simulate in vivo 
nanoparticle distributions and uptake in tumor tissues. 3D spheroid 
breast cancer cellular model was obtained using a TNB cancer cell line 
(MDA-MB-231 cells). TNB cancer is currently a priority in breast cancer 
therapy due to its decreased responsiveness to the current endocrine and 
targeted therapies. TNB cancer cells are mutated and lack of physio-
logical pathways like progesterone receptors (PR), estrogen receptors 
(ER) and human epidermal growth factor receptor 2 (HER2), being no- 
responsive to the treatment that targets these receptors (Lee and 
Djamgoz, 2018). In these attempts, estrogen-receptor positive breast 
cancer is currently well treated with hormonal therapies and have a 5- 
year breast cancer–survival of 99% at the stage I (tumor mass smaller 
than 2 cm without the involvement of lymph node), while estrogen re-
ceptor metastatic cancer has a median overall survival of 4–5 years. 
Conversely, TNB cancer has a poorer prognosis showing a 5-year breast 
cancer–survival of 85% at the stage I and a median overall survival of 
10–13 months for metastatic phenotype (Waks and Winer, 2019; Cha-
vez-MacGregor et al., 2017). These findings highlight the urgent priority 
to develop new therapies for TNB cancer that lacks targeted therapies in 
contrast to PR, ER and/or HER2 positive breast cancer (Al-Mahmood 
et al., 2018). For these reasons, the efforts in breast cancer research are 
mainly focused on TNB cancer and in line with this statement we 
decided to focus our work in the study of TNB 3D cancer cell models. 
Human fibroblast (20% of total cells) were used to stabilize the 3D 
structure of MDA-MB-231-based spheroids (Rustamov et al., 2019), thus 
providing also a better correspondence with in vivo pathological condi-
tions, where fibroblasts strongly affect the tumor proliferation (Kalluri 
and Zeisberg, 2006; Sahai et al., 2020). The cytotoxic activity of LinTT1- 
Lipo/D + S, bare-Lipo/D + S and the association of free DOX and SRF 
Fig. 6. In vitro cytotoxic activity of DOX and 
SRF, co-loaded LinTT1-functionalized lipo-
somes on MCF-7 (Panel A) and MDA-MB-231 
(Panel B) cell lines using 2D breast cancer 
cell models. Cytotoxic effect was reported as 
cell viability percentage (%) and evaluated 
as a function of incubation times and drug 
concentrations. Cell viability percentage (%) 
of therapeutic LinTT1-functionalized lipo-
somes was compared to therapeutic bare li-
posomes. Cellular viability percentage (%) 
was evaluated by using CellTiter-Glo lumi-
nescence assay. Cells treated with cell culture 
medium are the control and correspond to 
100% of cell viability for all tested concen-
trations at different times of incubation. Cells 
treated with empty LinTT1-Lipo demon-
strated a cell viability over 90% for all tested 
concentrations (data not shown). Results are 
the average of three independent experi-
ments ± S.D. Statistical significance was set 
at: *p < 0.05, **p < 0.01, and ***p < 0.001. 
Error bars, if not shown, are within symbols.   
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was evaluated in 3D spheroids of MDA-MB-231 cells and the differences 
for cell viability (%) among the treatments were obtained (Fig. 7). We 
have previously demonstrated that bare-Lipo/D + S and LinTT1-Lipo/D 
+ S increased the cytotoxic effect of combined payloads compared to the 
native drugs in 2D of breast cancer cells (Figs. 5 and 6). These results 
were similar in 3D spheroids where the cytotoxic effect of both bare- 
Lipo/D + S and LinTT1-Lipo/D + S was higher than the combination of 
two drugs in the free form for the MDA-MB-231 cells (Fig. 7). Conversely 
to 2D cell results, the cytotoxic effect of LinTT1-Lipo/D + S was higher 
than bare-Lipo/D + S for almost all tested incubation times and con-
centrations, in the 3D spheroids of MDA-MB-231 cells. Here, the cyto-
toxic effect of LinTT1-Lipo/D + S was higher than bare-Lipo/D + S from 
the lowest incubation time point (6 h) and these differences became 
more evident at long incubation time points, also at low drugs concen-
trations (Fig. 7). 
The cell viability was 66.7 ± 4.6% and 77.2 ± 3.7% for LinTT1-Lipo/ 
D + S and bare-Lipo/D + S, respectively, after 24 h of incubation at the 
DOX concentration of 0.5 µM and SRF corresponding concentration of 
0.17 µM. 
Similar differences were observed between the two formulations 
after 48 and 72 h of incubation. After 48 h of incubation the cell viability 
was 50.8 ± 4.9% and 65.4 ± 7.1% for LinTT1-Lipo/D + S and bare-Lipo/ 
D + S, respectively, at the DOX concentration of 0.5 µM and SRF cor-
responding concentration of 0.17 µM. A significant difference was also 
observed between the two formulations at the same incubation time 
point at the DOX concentration of 1 µM and SRF corresponding con-
centration of 0.35 µM, where the cell viability was 44.2 ± 3.6% and 58.6 
± 6.8% for LinTT1-Lipo/D + S and bare-Lipo/D + S, respectively. After 
72 h of incubation the difference between LinTT1-Lipo/D + S and bare- 
Lipo/D + S were still significant at the DOX concentration of 0.5 µM and 
SRF corresponding concentration of 0.17 µM, showing a cell viability of 
40.9 ± 4.1% and 56.4 ± 3.7%, respectively. Similar trend was found at 
the DOX concentration of 1 µM and SRF corresponding concentration of 
0.35 µM where spheroids treated with LinTT1-Lipo/D + S and bare- 
Lipo/D + S had a viability of 31.7 ± 3.3% and 43.1 ± 4.8%, respectively, 
after 72 h of incubation. Moreover, at this incubation time point, 
LinTT1-Lipo/D + S showed a higher cytotoxic effect than bare-Lipo/D +
S also at DOX concentration of 0.1 µM and SRF corresponding concen-
tration of 0.035 µM, showing a cell viability of 54.4 ± 5.1% and 67.2 ±
3.9%, respectively. Conversely with results obtained for MDA-MB-231 
2D cell model (Fig. 6B), in the 3D spheroids of MDA-MB-231 cells the 
data demonstrated an improved cytotoxic effect of LinTT1-Lipo/D + S 
compared to bare-Lipo/D + S also for long incubation time points (48 
and 72 h) (Fig. 7). 
This difference may depend on both, the “non-realistic interaction” 
between cancer cells in the 2D cell model that provided a higher uptake 
of nanoparticles (Behzadi et al., 2018), resulting in the lack of differ-
ences between functionalized and bare liposomes after long incubation 
time points, and also the hypoxic condition in the core of 3D spheroids 
that increased the overexpression of p32 protein receptors on breast 
cancer cell surface (Fogal et al., 2008; Song et al., 2019; Paasonen et al., 
2016). Moreover, results demonstrated that higher concentrations of 
chemotherapeutic agents were required in the 3D cell model in com-
parison to the 2D cell model in order to provide a similar cytotoxic ef-
fect. These results are in agreement with data previously reports for 
other chemotherapeutic drugs that are used in similar 3D spheroids of 
breast cancer model (Figueiredo et al., 2019), and depended on the 
higher proliferation of breast cancer cells in the 2D model than the 3D 
spheroid model, thus resulting in an increased anticancer efficacy of 
payloads in MDA-MB-231 cells when cultured as mono-layer model 
(Frohlich, 2018). 
3.7. 3D spheroids and interaction studies 
Next, the internalization and uptake of LinTT1-Lipo was qualita-
tively and quantitatively evaluated in 3D spheroids of MDA-MB-231 
cells with a diameter around 600 µm, using confocal laser scanning 
microscopy and flow cytometry, respectively (Fig. 8). The uptake of 
LinTT1-Lipo was evaluated at the incubation time points of 3 and 6 h, 
and was compared to the internalization of bare-Lipo. Positive events 
and the localization of the liposomes were evaluated through flow 
cytometry analysis and confocal laser scanning microscopy, respec-
tively. For these studies, fluorescently labeled bare-Lipo were synthe-
sized by adding a fluorescent lipid (DHPE-fluorescein, at 0.1% w/w) in 
the lipid bilayer during the preparation procedure, while LinTT1-Lipo 
resulted fluorescent thanks to the presence of fluorescent FAM mole-
cule in the peptide backbone structure. Flow cytometry analysis and 
confocal analyses were carried out using only 3D spheroids of MDA-MB- 
231 cells to better mimic an in vivo situation (Behzadi et al., 2018). 
Flow cytometry analysis demonstrated that LinTT1-Lipo were more 
taken-up and then significantly internalized by 3D spheroids of MDA- 
MB-231 cells than bare-Lipo, after 3 h of incubation. (Fig. 8A). The 
percentage of positive cells was 7.4 ± 2.1% and 25.3 ± 4.6% for bare- 
Lipo and LinTT1-Lipo (Fig. 8A), respectively. 
Uptake and internalization of LinTT1-Lipo increased by increasing 
the incubation time up to 6 h (Fig. 8A). After 6 h of incubation time, the 
percentage of positive cells were 30.3 ± 4.3% and 40.2 ± 2.5% for bare- 
Lipo and LinTT1-Lipo (Fig. 8A), respectively, that is more than double 
for bare liposomes and almost double for LinTT1-Lipo. The fluorescence 
of bare- and LinTT1-Lipo associated to the cell membrane of MDA-MB- 
231 cells forming the 3D spheroids, which are not internalized, was 
quenched using a trypan blue solution. Results suggested that bare-Lipo 
and LinTT1-Lipo have different pathways of interaction with 3D the 
spheroid tumor model of MDA-MB-231 cells. The increased interaction 
of LinTT1-Lipo with cells in comparison with bare-Lipo depends on the 
Fig. 7. In vitro cytotoxic activity of DOX and SRF free or co-loaded into bare- 
and LinTT1-functionalized liposomes in 3D spheroids of MDA-MB-231 cells. 
The cytotoxic activity was evaluated at different drug concentrations and in-
cubation times. Results are reported as cellular viability percentage (%) and 
were obtained by using RealTime-Glo MT Cell Viability Assay. Data is the 
average of three independent experiments ± S.D. Control is 3D spheroids of 
MDA-MB-231 cells that are treated with cell culture medium and corresponds to 
100% of cell viability for all tested concentrations at different times of incu-
bation (6, 24, 48 and 72 h). Spheroids treated with empty LinTT1-Lipo and 
empty bare-Lipo demonstrated a cell viability over 90% for all tested concen-
trations (data not shown). Differences were evaluated between cytotoxic effects 
of combined free DOX and SRF and drugs co-loaded liposomes (both bare and 
functionalized ones). Statistical significance was set at: *p < 0.05, **p < 0.01, 
and ***p < 0.001. Error bars, if not shown, are within symbols. 
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presence of p32 receptor on cancer cells’ membrane, as demonstrated 
for other LinTT1-functionalized nanoparticles through the pre- 
incubation of a blocking anti-p32 antibodies with cancer cells, that 
significantly inhibited the binding between cells and LinTT1- 
functionalized nanoparticles (Hunt et al., 2017). The higher internali-
zation of LinTT1-Lipo than bare-Lipo in MDA-MB-231 cells were in 
agreement with previous studies that demonstrated the increased 
cellular uptake of LinTT1-functionalized nanoparticles in comparison 
with bare nanoparticles on several cancer cells, including breast cancer 
ones (Simón-Gracia et al., 2018b; Hunt et al., 2017). 
Flow cytometry analysis (Fig. 8A) agreed with confocal analysis that 
qualitatively demonstrated that LinTT1-Lipo were more taken-up and 
internalized in 3D spheroids of MDA-MB-231 cells in a time-dependent 
manner (Fig. 8B). DAPI solution (blue) was used to stain the nuclei of 
MDA-MB-231 cells showing a spherical-like three-dimensional 
arrangement of spheroids (Fig. 8B). The interaction between liposomes 
(both bare and functionalized ones) and spheroids was evaluated using 
the light channel of AlexaFluor488® (green) that has the same adsorp-
tion and excitation wavelength of FAM group conjugated to peptide on 
LinTT1-Lipo and fluorescein group conjugated to DHPE lipid on bare- 
Lipo. Moreover, in agreement to flow cytometry data, the differences 
between bare- and LinTT1-Lipo are more significant for shorter incu-
bation time (3 h) than longer ones (6 h), despite the interaction between 
LinTT1-lipo and spheroids still remained clearly higher than the inter-
action between bare-Lipo and spheroids after 6 h of incubation. 
3.8. Primary human M2 macrophages-liposomes interaction study 
Currently, the targeting of M2 macrophages is one of the most 
promising approaches to design novel anticancer nanomedicines or 
potentiate the existing therapies (Cassetta and Pollard, 2018). Based on 
the evidence that M2 macrophages have an overexpression of p32 pro-
tein (Fogal et al., 2008), we studied the interaction between LinTT1-Lipo 
and these specific cells. Macrophages were collected from whole human 
blood and then differentiated in M2 phenotype, as described in the 
Experimental Section. The presence of surface specific markers for M2 
macrophages was evaluated using flow cytometry analysis and endorsed 
the proper differentiation of monocytes in M2 macrophages 
(Figure S12). The interaction study demonstrated that LinTT1-Lipo had 
a higher interaction rate with M2 macrophages than bare-Lipo at both 
short (1 h) and long (3 h) incubation times (Fig. 9). 
After 1 h of incubation the interaction rate was 5.7 ± 2.2% and 26.5 
± 2.6% for bare-Lipo and LinTT1-Lipo, respectively, while it was 19.4 ±
3.5% and 55.4 ± 4.6% for bare-Lipo and LinTT1-Lipo, respectively, after 
3 h of incubation with M2-macrophage. Differences depend on the 
LinTT1-peptide that is conjugated to the surface of liposomes and the 
links selectively p32 protein receptor overexpressed on the surface of M2 
macrophages (Torrieri et al., 2020). 
The effective amount of LinTT1-Lipo internalized by M2 macro-
phages was further studied by quenching the fluorescence of the lipo-
somes on the cell membrane of the macrophages with trypan blue 
solution. No-significant differences were obtained for the specific uptake 
and internalization of bare-Lipo with or without quenching agent (5.7 ±
2.2% versus 4.2 ± 1.2% and 19.4 ± 3.5% versus 16.2 ± 2.8% after 1 h 
and 3 h of incubation, respectively) (Fig. 9). Conversely, interaction 
study between LinTT1-Lipo and M2-like macrophage in presence of cell 
membrane quenching agent demonstrated that only part of the LinTT1- 
Lipo were taken-up and internalized in M2 macrophages, and the other 
part was only strongly associated onto the cell membrane (Fig. 9). After 
1 h of incubation with LinTT1-Lipo the positive events were 26.5 ± 2.6% 
versus 15.2 ± 2.4% and 55.4 ± 4.6% versus 27.8 ± 2.9% after 3 h of 
incubation, in absence and presence of the quenching agent, respec-
tively. Based on this, M2-macrophages can improve the accumulation of 
LinTT1-functionalized liposomes in the hypoxic area of tumor core. Our 
suggestion is based on the intrinsic ability of macrophages to accumulate 
themselves in the hypoxic area of tumor core (where the most abundant 
phenotype is M2-like), as described elsewhere (Casazza et al., 2013; 
Silva, 2017; Zhang et al., 2014; Qiu et al., 2018; Chen et al., 2019b; Pang 
et al., 2016). For this reason, M2-macrophages can represent a cellular 
carrier for a potential delivery of LinTT1-liposomes which are strongly 
associated, and partially internalized by M2-macrophages, in order to 
increase the accumulation of liposomes in hypoxic tumor area through a 
Fig. 8. In vitro interaction between bare- and LinTT1-funtionalized liposomes 
and 3D spheroids of MDA-MB-231 cells. The quantitative analysis of cellular 
uptake and internalization was evaluated by using flow cytometry analysis (A). 
500 µg mL− 1 of bare and LinTT1-functionalized liposomes were incubated with 
3D spheroids of MDA-MB-231 cells at 37 ◦C for 3 and 6 h. The obtained data 
were normalized using the untreated cells as a control. Fluorescent positive 
cells were evaluated at the incubation time herein reported. At least 10,000 
events were collected for each measurement. Qualitative analysis was obtained 
by using confocal laser scanning microscopy (B). DAPI (blue) was used to stain 
the nucleus, while Alexa Fluor 488 channel (green) was used to detect fluo-
rescence of bare- and LinTT1-Lipo. The merged panels show the interaction 
between bare and LinTT1-Lipo with 3D spheroids of MDA-MB-231 cells. Scale 
bar is 200 µm. Results are the average of three independent experiments ± S.D. 
Statistical significance was set at: *p < 0.05, **p < 0.01, and ***p < 0.001. 
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In this study, we constructed tumor-targeting nanovesicles by 
conjugating LinTT1 peptide to the surface of therapeutic liposomes. 
LinTT1-functionalized liposomes increased the therapeutic activity of 
two chemotherapeutic drugs, DOX and SRF, in both positive estrogen 
receptor (MCF-7) and triple negative breast cancer (MDA-MB-231) cells. 
The anticancer activity of the targeted liposomes also increased in 2D 
cell models compared to single chemotherapeutic drugs. LinTT1- 
functionalized liposomes were more internalized and taken-up in 3D 
spheroids of MDA-MB-231 cells than bare liposomes. The anticancer 
activity of DOX and SRF co-loaded LinTT1-functionalized liposomes also 
increased in 3D spheroids of MDA-MB-231 cells compared to both bare 
liposomes and combination of free drugs. LinTT1-functionalized lipo-
somes were partly internalized and partly associated to the external cell 
membranes of primary M2 macrophages. The amount of LinTT1- 
functionalized liposomes that is associated onto the surface of primary 
human M2 macrophages could be used as a potential mechanism to 
modulate the penetration and accumulation of targeting liposomes in 
the central portion of the hypoxic area of tumor tissues. These promising 
results highlight the potential use of DOX and SRF co-loaded LinTT1- 
functionalized liposomes as nanomedicines for the treatment of meta-
static TNB cancer. 
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Hirvonen, J., Santos, H.A., 2017. A multifunctional nanocomplex for enhanced cell 
uptake, endosomal escape and improved cancer therapeutic effect. Nanomedicine 
12, 1401–1420. 
Almeida, P.V., Shahbazi, M.A., Makila, E., Kaasalainen, M., Salonen, J., Hirvonen, J., 
Santos, H.A., 2014. Amine-modified hyaluronic acid-functionalized porous silicon 
nanoparticles for targeting breast cancer tumors. Nanoscale 6, 10377–10387. 
Anselmo, A.C., Mitragotri, S., 2019. Nanoparticles in the clinic: an update. Bioeng. 
Transl. Med. 4, e10143. 
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La Barbera, G., Laganà, A., 2016. The protein corona of circulating PEGylated 
liposomes. Biochim. Biophys. Acta (BBA)-Biomembr. 1858, 189–196. 
Pang, L., Qin, J., Han, L., Zhao, W., Liang, J., Xie, Z., Yang, P., Wang, J., 2016. Exploiting 
macrophages as targeted carrier to guide nanoparticles into glioma. Oncotarget 7, 
37081. 
Paolino, D., Accolla, M.L., Cilurzo, F., Cristiano, M.C., Cosco, D., Castelli, F., 
Sarpietro, M.G., Fresta, M., Celia, C., 2017. Interaction between PEG lipid and DSPE/ 
DSPC phospholipids: an insight of PEGylation degree and kinetics of de-PEGylation. 
Colloids Surf. B: Biointerf. 155, 266–275. 
Paolino, D., Cosco, D., Gaspari, M., Celano, M., Wolfram, J., Voce, P., Puxeddu, E., 
Filetti, S., Celia, C., Ferrari, M., 2014. Targeting the thyroid gland with thyroid- 
stimulating hormone (TSH)-nanoliposomes. Biomaterials 35, 7101–7109. 
Park, J.E., Dutta, B., Tse, S.W., Gupta, N., Tan, C.F., Low, J.K., Yeoh, K.W., Kon, O.L., 
Tam, J.P., Sze, S.K., 2019. Hypoxia-induced tumor exosomes promote M2-like 
macrophage polarization of infiltrating myeloid cells and microRNA-mediated 
metabolic shift. Oncogene 38, 5158–5173. 
Pasut, G., Paolino, D., Celia, C., Mero, A., Joseph, A.S., Wolfram, J., Cosco, D., 
Schiavon, O., Shen, H., Fresta, M., 2015. Polyethylene glycol (PEG)-dendron 
phospholipids as innovative constructs for the preparation of super stealth liposomes 
for anticancer therapy. J. Contr. Release 199, 106–113. 
Peerschke, E.I., Ghebrehiwet, B., 2014. cC1qR/CR and gC1qR/p33: observations in 
cancer. Mol. Immunol. 61, 100–109. 
Peerschke, E.I., Li, X., Eguchi, T., Aly, R., Chintala, N.K., Tan, K.S., Zauderer, M.G., 
Dembitzer, F.R., Beasley, M.B., Ghebrehiwet, B., 2019. Globular C1q receptor 
(gC1qR/p32/HABP1) is overexpressed in malignant pleural mesothelioma and is 
associated with increased survival in patients treated with chemotherapy. Front. 
Oncol. 9, 1042. 
Pitoia, F., Jerkovich, F., 2016. Selective use of sorafenib in the treatment of thyroid 
cancer. Drug Des. Devel. Ther. 10, 1119. 
Pozzi, D., Caracciolo, G., Digiacomo, L., Colapicchioni, V., Palchetti, S., Capriotti, A., 
Cavaliere, C., Chiozzi, R.Z., Puglisi, A., Laganà, A., 2015. The biomolecular corona of 
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